2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]i s [2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
AssigneeSyntex (U.S.A.) Inc.
InventorsJacob Berger, Robin D. Clark, Paul E. Weller, Douglas L. Wren
Life of this patent
Estimating the term…
Abstract
This invention relates to 2-(1'-azabicyclo[2.2.2]oct-3'S-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[de ]isoquinolin-1-one and 2-(1'-azabicyclo[2.2.2]oct-3'S-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1H-ben z[de]isoquinolin-1-one and their individual stereoisomers and uses and the processes for their making.
Claims23
A compound of Formula I:
- ##STR5## in which the dashed line denotes an optional double bond;
- and the pharmaceutically acceptable salts, individual stereoisomers, mixtures of isomers, N-oxide derivatives and O-.beta.-D-glucuronide conjugates thereof.
A method for treating a condition chosen from emesis, a gastro-intestinal disorder treatable with prokinetic agents, a cognitive disorder, psychosis, anxiety/depressive state, obsessive/compulsive behavior, hypertension, arrhythmia and pain in an animal in need of such treatment, which method comprises administering a therapeutically effective amount of a compound of Formula I:
- ##STR6## in which the dashed line denotes an optional double bond;
- or a pharmaceutically acceptable salt, individual stereoisomer, mixture of stereoisomers, N-oxide derivative or O-.beta.-D-glucuronide conjugate thereof.
Dependencies are inferred from the claim text.